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Abstract
Since its introduction to the market in 1963, bromhexine, an over-the-counter drug, has been investigated for its activity
in animal models and in humans with diverse respiratory conditions. Bromhexine is a derivate of the Adhatoda vasica
plant used in some countries for the treatment of various respiratory diseases. Bromhexine has been found to enhance
the secretion of various mucus components by modifying the physicochemical characteristics of mucus. These changes,
in turn, increase mucociliary clearance and reduce cough. Principal clinical research studies were primarily developed in
an era when stringent methodological approaches and good clinical practices were not developed yet. Clinical
studies were conducted mainly in patients with chronic bronchitis and in patients with various respiratory diseases, and
demonstrated the efficacy of bromhexine in improving respiratory symptoms. Furthermore, the co-administration
of antibiotics with bromhexine amplified the actions of the antibiotic. Although the clinical evidence shows
only modest but positive results, bromhexine is indicated for its mucoactive activity. Larger trials with adequate
methodology are required to identify when treatment with bromhexine can improve clinical outcomes.
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Background
Airway inflammation, mucus hypersecretion and impaired
mucociliary clearance are the major characteristics of a
variety of pulmonary diseases. Effective mucus clearance
is essential for lung health, and airway disease is a typical
consequence of poor clearance. Physiologically, mucus is a
gel with low viscosity and elasticity that is easily trans-
ported by ciliary action, whereas pathologic mucus has
higher viscosity and elasticity and is less easily cleared.
Furthermore, beating cilia are in contact with the mucus
layer and the contact is dependent, in part, on the rhe-
ology of the mucus. The transformation from healthy to
pathologic mucus occurs by multiple mechanisms [1].
These mechanisms include modifications in the quality,
quantity and physiochemical features of mucus.
Tracheobronchial secretions are principally watery
(approximately 96% water) with approximately 4%
mucus. The secretions form a layer over the ciliary epi-
thelium, which consists of a fluid periciliary solution that
enables the cilia to beat freely and propel the uppermost
gel layer up to the airways [2].
Airway mucus is a heterogeneous mixture of secreted
polypeptides, cells and cellular debris that is present in the
fluid lining the airway surface subphase or is tethered to-
gether at the fluid surface by oligomeric mucin complexes
[3]. Other locally synthesized macromolecules, including
lysozyme, lactoferrin and immunoglobulins, are present in
mucus. The total volume of secretions cleared per day in
humans is not known, but it is estimated to be 10–50 ml
[4]. This amount can increase up to 200 ml in individuals
with chronic bronchitis during an exacerbation.
Elevated mucin production increases the number of
intracellular mucin stores contained within airway
secretory cells; in addition, increased mucin exocytosis in-
creases the thickness and viscosity of the extracellular
mucus gel positioned above the surface epithelium [3].
Numerous mucoactive agents with a variety of actions on
the airways or secretions have been used. Patients who are
most likely to benefit from mucoactive therapy usually
have a history of increased sputum expectoration and a
preserved airflow. However, the effectiveness of therapy in
an individual patient can be difficult to assess [5].
Adhatoda vasica nees (Acanthaceae), commonly known
as vasaka, is distributed throughout India up to an altitude
of 1300 m. Adhatoda vasica is a medicinal plant native to
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Asia, widely used in Siddha, Ayurvedic and Unani systems
of medicine [6]. Adhatoda vasica is well known for its use
in respiratory diseases. Both pure vasicine and its deriva-
tives have been studied for their bronchodilatory and anti-
tussive effects. Amin and Mehta were the first to isolate
vasicinone, a component with bronchodilatory activity,
in crystalline form from the leaves of Adhatoda
vasica [7]. One of the derivatives of vasicinone is
bromhexine (BHC) or bromhexine hydrochloride (N-
cyclohexyl-N-methyl-(2-amino-3,5-dibromo-benzyl)amine
hydrochloride). Since its introduction to the market in
1963, the drug has been investigated for its effects in ani-
mal models and in human with diverse respiratory dis-
eases. In addition to clinical aspects, these studies have
focused on the effects of the drug on mucus, sputum and
mucociliary activity. In the present overview, we will high-
light the principal basic findings about the mechanisms of
action of BHC. In addition, we report a series of clinical
findings in adults and children.
Mechanisms of action
The mechanisms of action of BHC are complex and re-
main incompletely explored. To date, few has been re-
ported regarding the cellular effects of the drug on the
respiratory tract. Studies in animals and humans have
reported actions that influence the production of muco-
substances, sputum quality and quantity, ciliary activity,
antibiotic penetration and cough severity and frequency.
These actions characterize the basic mucoactive activity
of BHC and differentiate it from other drugs. Preclinical
studies are summarized in Table 1.
Effects of BHC on the production of mucosubstances
In 1966, Merker reported that the administration of
BHC is followed by a quantitative and qualitative effect
on secretory epithelial cells in the medium and small
bronchi of the rat using electron microscopy [8]. In this
pioneer study, BHC was injected at a dose of 4–20 mg/
kg/24 hrs over a period of 2, 4 or 6 days. These
observations were later confirmed in human tissue by
Gieseking and Baldamus [9]. This later study was con-
ducted on 9 patients with tuberculosis with cavitation or
carcinoma before and after partial lung resection. Biopsy
samples were taken before resection and BHC was given
at a dose of 4 mg three times daily. BHC considerably
increased secretion activity in the seromucous glands of
the bronchial mucosa. The secretion product of the
glandular serous epithelial cells consisted of large homo-
geneous globular granules. These granules exhibited ul-
trastructural characteristics that were strikingly similar
to lysosomes. No quantitative changes were observed in
ciliated or goblet cells.
Janatuinen and Korhonen evaluated the effect of BHC
on mucosubstance production in 15 male guinea pigs [10].
Animals were divided into 5 groups: control, treated with
saline, treated with 10 mg/kg BHC intraperitoneally,
treated with 10 mg/kg BHC subcutaneously for 3 day and
treated with 5 mg/kg BHC subcutaneously for 7 days. Sam-
ples from the trachea, salivary glands and duodena were
examined to determine the number of goblet cells and for
histochemical staining for mucosubstance investigations.
The secretory material in tracheobronchial goblet cells
consisted of acid mucosubstances containing both sulphate
and carboxyl groups in addition to periodate reactive ma-
terial. Drug treatment induced changes in the synthesis of
acid mucosubstances, resulting in secretory material in the
tracheal mucosa that consisted largely of neutral periodate
reactive substances. Higher doses of BHC caused a signifi-
cant decrease in the total number of goblet cells with
secretory material, especially the cells containing sulphated
mucosubstances. Authors attributed these findings to the
increased mobilization of the secretory products from the
cells. The drug did not induce changes in the salivary
glands or in the duodenal goblet cells.
Gil and Thurnheer evaluated the effect of BHC on the
ultrastructure of type II alveolar cells obtained from
white rat lungs [11]. In this study, the drug was adminis-
tered through a gastric tube (200 mg/kg/day) for 3 days.
Table 1 Summary of preclinical studies on bromhexine
Author Cell type BHC dosage Outcomes
Merker 1966
[8]
Rats, bronchial secretory cells 4-20 mg/kg/24 h parenteral Quantitative and qualitative effect on mucus production
Janatuinen
1969 [10]
Guinea pigs, bronchial goblet cells 5-10 mg/kg/24 h parenteral Reduction in goblet cells, increased secretory material in airways
Gil 1971 [11] Rats, type II alveolar cells 200 mg/kg/24 h enteral Increased secretion of phospholipids in alveolar space
Harada 1977
[12]




Rabbits, lung and liver tissues 10 mg/kg intravenous Rapid stimulation of phospholipid synthesis
Martin 1993
[27]
Pigs, rheological characteristics of
tracheal mucus
0,5 mg/kg Increased concentration of oxytetracycline within the secreted
mucus and reversed mucospastic activity of oxytetracycline in vivo
BHC bromhexine hydrochloride
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The results showed that type II alveolar epithelial cells
presented with lamellated bodies of unusual size, and
many cells were “stuffed” with lamellated bodies in the
BHC group. The morphometric evaluation indicated a
volumetric density of lamellated bodies within type II al-
veolar cells of 20 ± 0.6% in the treated group with BHC
and 18 ± 0.8% in the control group. The volumetric
density of alveolar type II cells within the lung was 11.3
± 1.5% in the treated group and 6.8 ± 1.8% in the control
group. These data indicate a considerable increase in the
number of lamellated bodies in lung parenchyma from
1.22% in controls to 2.26% in the BHC group. Alveolar
type II cells are considered to be major sources of alveo-
lar surfactant. This study indicates that BHC influenced
the metabolism of alveolar type II cells, which might
lead to an increase in the secretion of phospholipids into
the alveolar space.
Harada et al. evaluated the effect of an intravenous injec-
tion of 4 mg of BHC on tracheal mucosa secretory activity
in adult dogs [12]. The secretory activity was evaluated by
observing ultrastructural mucosal changes after 15, 30 and
60 min. using electron-microscopy scanning. Drug admin-
istration induced a rapid increase in the output of secre-
tion from normal tracheal mucosa. Both goblet cells of the
epithelium and the sero-mucinous glands in the tunica
propria participated in the production of the tracheal dis-
charge. Two types of secretions were observed: spherical
mucus granules derived from goblet cells and submucosal
mucus glands; and a fine floccular substance that stuck the
tips of cilia together and appeared to be serous discharge
or transudate. Sixty minutes after drug injection, non-
granules were observed on the epithelial surface and the
submucosal glands were shrunken and empty. These data
demonstrate an active action of BHC on tracheal cells and
consequently on mucociliary clearance.
Lorenz et al. demonstrated that the administration of
the BHC metabolite VIII to 36 pregnant women with a
gestational age of 29–32 weeks at a dose of 1 mg/kg/day
for 5 days induced fetal surfactant production [13].
Compared to controls, an increase of more than 50% in
total phospholipid concentration, lecithin concentration
and lecithin/sphingomyelin ratio was observed. The ad-
ministration of BHC at doses of 300–600 mg orally daily
or 100 mg intravenously for five days did not induce the
previously mentioned changes. The authors attributed
this finding to the low dose of BHC. The incorporation
of lauric acid, palmitic acid and oleic acid into phospho-
lipids of lung and liver tissues of control rabbits and rab-
bits treated intravenously with BHC or ambroxol at
10 mg/kg was investigated by Von Wichert et al. using
radioactively labelled precursors [14]. A marked increase
(up to 200%) in palmitic acid incorporation into phosphat-
idylcholine (lecithin) and phosphatidyl-ethanolamine in
the lung was observed but was not present in the liver.
The observed effects were more marked in shorter experi-
ments (analysis 2 hrs after drug injection) than after treat-
ments for 7 days. The incorporation of lauric acid and
oleic acid into lung phospholipids was not influenced by
treatment. These data demonstrate that BHC stimulates
phospholipid synthesis.
Crimi et al. investigated the effect of 15 days of treat-
ment with BHC 48 mg/day on phospholipids in broncho-
alveolar fluid in 13 patients suffering from chronic
bronchitis [15]. After treatment, the concentration of total
phospholipids significantly increased (p < 0.05). This in-
crease was not associated with variations in the phospho-
lipid fractions. The authors hypothesized that this increase
may be attributed to an increase in the phospholipid con-
tent of type II cells or Clara’s cells or a decrease in the
degradation of phospholipids. These changes may enhance
mucociliary clearance in the lung.
Membrane phospholipids constitute a permeability bar-
rier, modulate the functional properties of membrane-
associated activities, provide a matrix for the assembly
and function of a wide variety of catalytic processes, and
act as donors during the synthesis of macromolecules
[16]. Furthermore, peroxidation of membrane phospho-
lipids acyl chains produces agents that play a causal role
in various pathological process [16, 17].
Effect of BHC on sputum
Flavell Matts et al. investigated the effect of BHC on
sputum fiber systems during exacerbations of pulmonary
disease in 53 patients between 15 and 86 years old with
asthmatic bronchitis and acute or chronic bronchitis
[18]. Morning sputum was collected three times weekly
and fixed smears were stained and observed under fluor-
escent and polarized light to examine DNA or mucopoly-
saccharide (MPS) fiber systems, respectively. Thirty-one
patients were treated with antibiotics and BHC, 14 pa-
tients were treated with BHC, only and 8 patients with an-
tibiotics only. BHC was administered at a dose of 8–
32 mg 3 times daily. The results demonstrated that when
patients responded to antibiotic treatment, DNA fibers
disappeared within a week. However, in some patients, the
amount of sputum was not reduced after antibiotic ther-
apy even after DNA fibers disappeared; this was due to
the presence of MPS fibers. In patients treated with BHC,
the MPS fibers usually disappeared within 7–12 days
(average 10 days). Moreover, patients in the BHC group
demonstrated clinical progress in that they were more able
to expectorate and sputum production markedly de-
creased. The authors concluded that antibiotics did not
affect the MPS fibers, but BHC therapy could reduce or
entirely remove these fibers from the sputum.
In a single-blind study, Bürgi evaluated the effect of
BHC and guaifenesin on the fiber system and the viscos-
ity of sputum in 22 adult patients with chronic
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bronchitis [19]. Seventeen patients completed the cross-
over study. For 2 weeks, the first group of 8 patients
were allocated to receive 3x8 mg BHC syrup daily. Then,
subjects received 3x100 mg of guaifenesin syrup for an
additional 2 weeks. The remaining patients received
treatments in the reverse order. Glycoprotein (GP) fibers
in sputum and sputum viscosity were evaluated at
weekly intervals in all patients. Investigations were car-
ried out with a rotational Viscotester under thermostable
conditions with a constant shear rate of 180 s−1. The re-
sults demonstrated that treatment with BHC progres-
sively reduced the fiber content of sputum, which
increased again after subsequent treatment with guaife-
nesin. Irrespective of the treatment order, BHC was
clearly superior with regard to the effects on GP fibers
(p < 0.01). Sputum viscosity decreased significantly in the
BHC group (p < 0.01). It is believed that a reduction in
sputum fiber content decreased viscosity.
The effects of various drugs, including BHC, on sputum
viscoeleasticity in 40 adults with chronic pulmonary dis-
eases (excluding asthma) were investigated by Shimura et
al. [20]. Patients were allocated into 5 groups: a control
group, a BHC group (24 mg/day), an ambroxol group
(90 mg/day); an α-chymotrypsin group (100 cu.u/day ad-
ministered total cavity) and a serratiopeptidase group
(30 mg/day). The treatment lasted for one week. Visco-
elastic measurements were obtained with a Raised Cosine
Pulse (RCP) method using a coaxial cylinder rheometer.
The RCP strain with a frequency of ωο 1.05 rad.sec −1 was
added by applying one cycle oscillation with an amplitude
of 5° to the outer cylinder and the Fourier transformation
of this stress was performed to obtain a complex shear
modulus (G’: storage modulus and G”: loss modulus). The
results demonstrated that absolute values of G’ and G” at
a frequency of ω5x10−1rad.sec−1 before and after the treat-
ment were significantly decreased (0.005 < p < 0.01) only
in the BHC group. In the BHC group, the frequency de-
pendence of G’ and G" remained unchanged. On the other
hand, chymotrypsin and serratiopeptidase (proteolytic en-
zymes) markedly changed the frequency dependence of
the sputum on G’ and G”. These data indicate that BHC
does not influence the molecular structure of the mucus,
whereas the aforementioned proteolytic enzymes break
down the linkage between structural subunits of the
sputum.
In contrast to these data, a study by Langlands [21]
did not report any significant changes after BHC treat-
ment. In this study, the effects of BHC were compared
with those of placebo in a double blind clinical trial in
patients with exacerbations of chronic bronchitis who
also had mucoid sputum. Treatment with either BHC
8 mg three times a day or with identical placebo tablets
was continued for 14 days. There was no significant effect
on the characteristics of the sputum, the improvement in
ventilatory capacity, or clinical characteristics in patients
who had been treated with BHC. Details of the study are
reported later. Similarly, a report with a higher dose of
BHC was published later [22]. It stated that the effects of
48 mg of BHC daily for 2–3 weeks were indistinguishable
from those of placebo tablets with respect to the stickiness
of sputum, difficulty of expectoration, or time taken to
clear the chest in the morning. Reasons behind these con-
trasting results are discussed later.
Sputum samples of 20 patients with allergic asthma
and the sputum pool of 10 healthy men were analyzed
before and after the administration of BHC [23]. BHC
was administered at the following doses: 3x8 mg from
the first to the 3rd day, 2x8 mg on the 4th and 5th days
and finally 4x4 mg from the 6th day onward until the
10th day. Sputum samples were characterized by elec-
trophoresis using biochemical and immunological
methods. After treatment all primary demonstrable
protein components showed a marked increase, espe-
cially gamma globulins. This rise was interpreted as the
result of increased secretion of already synthesized im-
munoglobulin molecules. Similar observations were
reported by Kado, who confirmed increased concentra-
tions of IgA and IgG in bronchial washings after BHC
treatment in 13 patients with chronic bronchial infec-
tions [24].
Effect on ciliary clearance
Thomson et al. investigated the effect of BHC on muco-
ciliary removal rate in 9 adult subjects with chronic
bronchitis (simple, mucopurulent and obstructive) [25].
Each patient was treated for 14 days with 16 mg of BHC
three times daily. Mucociliary removal activity was eval-
uated using labelled aerosol (99mTc) after inhaling a
dose of <50 μCi. Clearance of the radioactivity was faster
in the patients than in the normal group. The amount
cleared at 6 h increased by 6.8% after treatment with the
drug (p < 0.05), which represents an increase of 14.5%
over radioactivity cleared in the control run. Scanning of
the lung after inhalation showed that tracer particles
penetrated further and were deposited nearer to the
periphery of the lung after BHC treatment than after
control treatment and the differences were statistically
significant (p < 0.01).
Pavia et al. evaluated the effect of BHC and other ex-
pectorant agents on tracheobronchial clearance in 43 pa-
tients with chronic bronchitis using a radioaerosol tracer
technique [26]. Following the inhalation of the radioaer-
osol under strictly controlled conditions, its clearance
from the lungs by means of the mucociliary system and
productive cough were monitored for 6 h. Treatment
with bromhexine, like other drugs (guaifenesin, 2-
mercapto-ethane sulphonate and hypertonic saline
1.21 M), significantly enhanced lung clearance.
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Effect of BHC on antibiotic penetration
Martin et al. investigated the influence of the combined
administration of BHC and oxytetracycline hydrochlor-
ide on the rheological characteristics of tracheal mucus
in three adult mini-pigs [27]. A twice-daily dosage of
oxytetracycline (40 mg kg − 1) and BHC (0.5 mg kg − 1)
was employed. Mucus was collected daily from open-
ended tracheal pouches established surgically in the
mini-pigs. The viscoelastic properties of each mucus
sample were determined using creep compliance analysis
in a rheometer. The results showed that oxytetracycline
increased the residual shear viscosity (p < 0.01) and the
instantaneous compliance (p < 0.01). When BHC was co-
administered with oxytetracycline, all of these changes
were abolished. Data suggest that BHC increased the
concentration of oxytetracycline within the secreted
mucus and reversed the mucospastic activity of oxytetra-
cycline in vivo.
Bergogne-Berezin et al. evaluated the influence of
BHC on the penetration of erythromycin into bronchial
secretions [28]. In a double blind placebo controlled
study 22 patients who had undergone bronchoscopy re-
ceived either erythromycin (day 0: 0 mg; day 1: 1000 mg;
day 2: 1500 mg, day 3: 500 mg) and placebo or erythro-
mycin (same as the control group) together with BHC
(day 0: 8 mg; day 1: 12 mg; day 2: 12 mg; day 3: 4 mg).
Eighteen patients completed the study. Erythromycin
concentration was determined in serum and in broncho-
alveolar fluid collected by bronchoscopy after treatment.
In the BHC group, the antibiotic concentration was
0.61-3.2 μg/ml (mean 1.55 μg/ml), whereas in the pla-
cebo group the antibiotic concentration was 0.4-1.6 ug/
ml (mean 1.05 μg/ml). The mean ratio of bronchial/
serum level of erythromycin in the BHC group was 0.46
vs 0.25 μg/ml in the control group (p = 0.05). This study
revealed a significant increase in the ratio between bron-
chial levels and serum concentrations of erythromycin
when erythromycin was administered in combination
with BHC. These data suggest that BHC enhances
erythromycin concentration in bronchial fluid.
Later clinical studies verified that combination treat-
ment with BHC and antibiotics was associated with fa-
vorable clinical responses. A multicenter double blind
trial by Roa and Dantes reported a significant reduction
in symptoms such as cough discomfort, cough fre-
quency, ease of expectoration and sputum volume in the
group treated with amoxicillin plus BHC with respect to
the group treated with amoxicillin alone [29]. Details of
these studies are reported below.
Cough
Various clinical studies have demonstrated that BHC in-
fluences cough. Lal and Bhalla demonstrated that treat-
ment with BHC leads to a reduction in expectoration
and reduced the severity/frequency of coughing [30].
The alleviation of cough and the normalization of expec-
toration have been described in patients with chronic
obstructive lung disease in a study by Iaia and Marenco
[31]. Details of these and other observations are de-
scribed in the subsequent clinical studies section.
Efficacy and safety of bromhexine in adults
Studies in animal models have raised clinical interest in
BHC. Numerous studies in adults with mucus hyperse-
cretion have subsequently been conducted. Herein we
analyze the fundamental studies present in the literature
(Table 2). Most of these studies were performed in sub-
jects with chronic obstructive bronchitis.
Randomized controlled trials
Nesswetha [32] enrolled 242 patients with mixed re-
spiratory conditions (chronic and acute bronchitis, colds
and upper respiratory tract infections) in three different
double blind randomized controlled trials. Participants
received BHC 5 mg three times daily (tid) or placebo for
at least four days. Clinical endpoints (cough, sputum vis-
cosity, disability) showed that frequent cough (every two
to five minutes) was less prevalent in the active treat-
ment arm (8.6%, p < 0.02) compared to the placebo
group (15.2%). The drugs were well tolerated, without
any significant adverse effects reported.
Gent et al. [33] described the effects of BHC on pul-
monary function in a cross sectional, double blind, pla-
cebo controlled study that included 48 patients (19–64
years old) with chronic bronchitis (n = 23), asthma (n = 9),
emphysema (n = 8) and diffuse parenchymal lung disease
(n = 8), presenting with difficulty in the expectoration of
sputum. Each condition was diagnosed on the basis of the
current diagnostic criteria. The measured outcomes were
functional residual capacity (FRC), forced expiratory vol-
ume in one second (FEV1), total-body plethysmography,
and clinical improvement. Outcomes were measured be-
fore the start of the first treatment, at the transition of the
treatment arm and at the end of the observation period.
After the randomization and the first week without treat-
ment, patients received BHC tablets 8 mg three times a
day (tid) or placebo for one week. In the third week of the
study, subjects received the other treatment. The group
treated with BHC had a significantly higher number of pa-
tients showing clinical and functional improvement. FRC
and FEV1 measures were not significantly different be-
tween the two groups. The adverse effects of BHC in-
cluded diarrhea (n = 1) and headache (n = 1).
Langlands [21] tested the effectiveness of BHC in pa-
tients admitted to the hospital for the exacerbation of
chronic bronchitis. Twenty-seven patients were random-
ized to receive bromhexine 8 mg tid or placebo for
2 weeks. The measured outcomes included respiratory
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Table 2 Summary of clinical study on bromhexine






Observational Biopsy from 9 adult patients with
cavitated tubercolosis or carcinoma
4 mg 3 times/
24 h
Increased secretion activity











Observational 13 adult patients with chronic
bronchitis






Observational 53 adult patients with asthmatic





















Observational 40 adults with chronic pulmonary
diseases (excluding asthma)
24 mg/24 h BHC does not influence the












No significant difference in
respiratory function or mucus
properties





42 adult patients with chronic
bronchitis





Observational 20 adult patients with allergic
asthma





Observational 13 adult patients with chronic
bronchial infections
- Increased concentrations of





Observational 9 adult subjects with chronic
bronchitis
48 mg/24 h Increased mucociliary clearence -
Pavia 1979
[26]
Observational 43 adult patients with chronic
bronchitis







22 adult patients undergone
bronchoscopy and received
erythromycin










392 adult patients hospitalized for
uncomplicated bacterial lower
respiratory tract infections receiving
amoxicillin











41 adult patients with stable chronic
obstructive bronchitis receiving
oxytetracycline
48 mg/24 h Better subjective evaluation
of sputum stickiness and
physician assessment of
outcome
Headache (n = 2)






242 adult patients with mixed
respiratory conditions








48 adult patients with chronic
bronchitis, asthma, emphysema or
diffuse parenchymal lung disease
24 mg/24 h Overall clinical and functional
improvement
Diarrhea (n = 1)






22 adult patients recovering from an
exacerbation of chronic obstructive
bronchitis









61 adult patients with chronic
bronchitis
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31 adult patients with chronic
bronchitis
24 mg/24 h Reduced symptoms, increased









102 hospitalized adult patients with
lower respiratory tract infections
treated with oxytetracycline
32 mg/24 h Higher rate of favorable










12 adult patients with chronic
bronchitis











237 adult patients with chronic
obstructive lung disease
60 mg/24 h decrease in cough, dyspnea
and sputum volume; easier
expectoration; improved
auscultatory findings and
improved FEV1 and PEFR;








28 adult patients with acute
bronchitis or exacerbation of chronic
bronchitis receiving amoxycillin
24 mg/24 h Reduced symptom severity








88 adult patients with exacerbation
of bronchiectasis










38 adult patients with chronic
obstructive bronchitis
48 mg/24 h Reduced sputum viscosity and
increased expectoration volume







177 adult patients with cough due to
uncomplicated upper respiratory
tract infections
24 mg/24 h Better cough relief Mixed (pruritus,
diarrhea, abdominal






30 children with acute sinus
inflammation receiving amoxycillin
48 mg/24 h Reduced nasal secretions,















Observational 30 children with clinical symptom of
mucus retention (asthma, common
cold and bronchiolitis)
0.5 mg/kg Overall clinical improvement










Observational 37 children with bronchitis, common
cold, asthmatic bronchitis, asthma
and bronchiectasis




Observational 32 children with upper respiratory










32 children hospitalized for acute
bronchitis








40 children with hypersecretory
bronchopulmonary diseases (acute,
asthmatic or recurrent bronchitis)




regurgitation (n = 2)
Diarrhea (n = 1)
Boner 1984
[52]





and better resolution in
patients with acute episodes
Gastric intolerance
(n = 3)
IgA immunoglobulin A, IgG immunoglobulin G, FEV1 forced expiratory flow 1st second, PEFR peak expiratory flow rate, BHC bromhexine hydrochloride, − = not available
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function (FEV1; forced vital capacity, FVC; peak expira-
tory flow rate, PEFR). Sputum viscosity and sputum vol-
ume were also compared. The authors did not find any
statistically significant difference in respiratory function
or mucus properties. One patient treated with BHC
complained of nausea.
In 1970 Hamilton and colleagues [34] explored the
rheological mucus and pulmonary functional effects of
BHC in patients recovering from an exacerbation of
chronic obstructive bronchitis. Twenty-two patients
(age 53.2 ± 8.9 years) were randomized in a double
blind manner to receive placebo (n = 10) or BHC (n = 12)
16 mg thrice daily for 11 days after an exacerbation of
chronic bronchitis. Outcomes were measured at the be-
ginning of the study, daily during the trial and four days
after the end of the treatment. Functional outcomes in-
cluded FEV1 and FVC, measured with a forced expiratory
spirogram. Mucus viscosity and daily sputum volume were
measured to assess rheological effects of BHC. The same
physician performed the clinical assessment at the begin-
ning and at the end of the study. The results showed a
statistically significant increase in sputum production
(p < 0.01) and a significant reduction (p < 0.01) of sputum
viscosity in patients receiving BHC. Neither spirometry
values nor clinical improvement were statistically signifi-
cant between the groups. BHC was well tolerated, and did
not exhibit significant hemato-chemical alterations.
In the same year, Christensen et al. [35] performed an-
other randomized controlled trial in patients with
chronic bronchitis (61 patients, aged 55.4 years). Sixty-
one patients with a diagnosis of chronic obstructive
bronchitis were divided into three groups based on dis-
ease severity and received BHC 24 mg daily or placebo
for six months. Mucolytic activity was evaluated by
assessing the variation of functional (FEV1; VC, vital
capacity; PEFR) and clinical (days of illness, antibiotic
consumption and subjective assessment) outcomes during
the study period. The FEV1 was significantly different (p =
0.01) in patients with moderate disease. Clinical endpoints
indicated that a greater proportion of patients felt better
and rates of illness were lower among those who took
BHC. Safety data were not reported.
The single blind study by Condie [36], performed in a
mining area during the winter period, included 31 pa-
tients with chronic bronchitis who received BHC 8 mg
three times daily or placebo for six weeks. The effects of
treatment were evaluated on both clinical (symptoms,
sputum characteristics) and functional parameters
(PEFR). The results showed a subjective reduction of
symptoms and an increased sputum volume in individ-
uals who had taken BHC; PEFR was significantly in-
creased after six weeks of treatment (p < 0.05). Three
patients complained of gastrointestinal side effects (nau-
sea and abdominal distension).
Matts conducted a double blind randomized trial on
102 hospitalized patients (mean age: 52 years) with lower
respiratory tract infections (chronic bronchitis exacerba-
tion, pneumonia, acute bronchitis) [37]. Both groups
were treated with oxytetracycline 250 mg 4 times daily
and one arm also received BHC 8 mg every 6 h for
10 days. Endpoints included the overall response to
treatment as assessed by clinical and radiological im-
provements (rated as good, moderate or failed) and
length of stay in the hospital. Sixty-seven percent of pa-
tients who had received BHC exhibited a favorable re-
sponse to treatment, compared to 51% of patients who
had received antibiotics only (p > 0.05). In addition, pa-
tients treated with BHC exhibited a faster recovery and a
significantly shorter hospitalization stay (9.4 vs 11.2 days,
p < 0.001). Twenty-two patients in the BHC group and
21 patients in the oxytetracycline alone group reported
side effects that were primarily associated with the
gastrointestinal system (nausea and anorexia).
Lal and Bhalla [30] studied the effect of BHC 16 mg 3
times daily in patients with stable chronic obstructive
bronchitis in a randomized crossover placebo-controlled
trial. Out of the 41 patients enrolled (mean age:
55.9 years) only 36 completed the 8 week study. Out-
comes were clinical (subjective symptoms, physician
evaluation) and functional (FEV1; PEFR; VC). All pa-
tients received oxytetracycline 500 mg twice a day dur-
ing the study. The patients who received BHC exhibited
better outcomes in terms of the subjective evaluation of
sputum stickiness (p < 0.05) and the physician assess-
ment of outcome (p < 0.05). No significant differences
were detected in pulmonary function tests. Two patients
complained of headache and two patients reported ex-
periencing stomach pain during treatment with BHC.
In 1975, Armstrong conducted another randomized
crossover placebo-controlled trial of BHC 24 mg tid for
4 weeks in 12 patients with chronic bronchitis [38]. Only
ten subjects completed the 10 week trial. The effects of
BHC were evaluated with functional measures (FEV1,
FVC and PEFR) and clinical outcomes (sputum charac-
teristics, auscultatory findings, dyspnea, cough, subject-
ive ease to expectoration). The results demonstrated that
patients who were treated with BHC exhibited increased
expectoration (p < 0.05) associated with improved aus-
cultatory findings (p < 0.004). PEFR was significantly im-
proved (p < 0.02) in patients receiving BHC. Two
patients reported adverse effects (1 patient reported
headache and nausea, 1 patient reported dizziness).
An Italian multicenter randomized controlled trial by
Valente [39] and colleagues evaluated the efficacy of
BHC in patients with chronic obstructive lung disease.
Two hundred and thirty-seven outpatients were selected
from 7 Italian clinical centers and were randomized in
double blind manner to receive either placebo or BHC
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30 mg twice a day for 14 days. The authors evaluated
sputum volume and quality, symptoms (expectoration,
cough, dyspnea, and auscultatory thoracic symptoms),
FEV1, PEFR and residual volume (RV) as clinical and
functional outcomes. Patients treated with BHC showed
a statistically significant decrease in cough and sputum
volume, easier expectoration, improved auscultatory
findings and decreased dyspnea (p < 0.01) compared to pa-
tients who had received a placebo. FEV1 and PEFR were
significantly improved in patients treated with BHC in
comparison to patients who received a placebo (p < 0.01).
The results of the clinical assessment demonstrated higher
rates of treatment efficacy in the treatment arm (p < 0.01).
The treatment was well tolerated with only one case of
withdrawal due to vomiting and gastralgia. No hemato-
chemical alterations were observed.
Bienvenido D. Alora [40] evaluated the effects of dual
therapy with BHC and amoxicillin in patients with
acute bronchitis or an exacerbation of chronic bron-
chitis. Twenty-eight patients (14 with acute bronchitis
and 14 presenting with an exacerbation of chronic
bronchitis) were enrolled in the study; patients were
randomized to receive amoxicillin alone (n = 13) or
amoxicillin plus BHC (n = 15). Endpoints included a re-
duction in the nominal scale of symptoms and sputum
volume. Patients who had received BHC demonstrated
a reduction in symptom severity (p < 0.001) and bacter-
ial elimination was higher than in subjects treated with
amoxicillin alone.
In 1991, Olivieri and colleagues [41] studied the effects
of BHC in patients with radiological evidence of bron-
chiectasis and a productive cough during an exacerba-
tion. The study was a double blind, randomized,
multicenter study including 88 patients who received
BHC 30 mg three times a day or placebo three times a
day for 15 days. A ceftazidine 1 g intramuscular injection
was administered daily for the first week. The outcomes
included the clinical evaluation of cough, auscultatory
findings and expectoration difficulty using an arbitrary
four-point scale and FEV1 measurements. Both clinical
and functional outcomes were improved in patients who
had been treated with BHC.
More recently, Roa and Dantes [29] published a
double blind multicenter randomized controlled trial on
patients admitted to the hospital for uncomplicated bac-
terial lower respiratory tract infections (LRTIs). Subjects
with susceptible bacteria according to sputum culture
were randomized to receive amoxicillin (250 mg 4
times/day, n = 200, mean age of 32 years old) or amoxi-
cillin plus BHC (250 mg + 8 mg 4 times/day, n = 192,
mean age of 32 years old) for 5 to 7 days. The endpoints
consisted of the clinical resolution of the episode of
LRTI; subjective dyspnea, cough and expectoration mea-
sured with a visual analog scale (VAS); and the
eradication of the bacterial infection. Patients treated
with a combination of amoxicillin and bromhexine ex-
hibited a better overall resolution of cough (p < 0.001)
and increased expectoration in the first day of treatment
(p < 0.001) and a greater decrease of symptoms in the
first days of treatment.
Comparative studies
Aylward [42] explored the expectorant effects of s-
carboxymethylcysteine and BHC in patients with chronic
obstructive bronchitis in a double blind comparison
study. Thirty outpatients (age 56.2 years) with a recent
exacerbation were randomized to receive BHC 16 mg or
s-carboxymethylcysteine 750 mg thrice a day for ten
days. Both groups reported a reduced viscosity of spu-
tum associated with an increased expectoration volume.
No significant differences were detected in pulmonary
function tests (FEV1, FVC, and PEFR). Two patients
(One in each group) reported that they had experienced
gastrointestinal adverse effects.
A recent randomized double blind parallel trial [43]
compared BHC to a phytomedicine syrup (KJ) and pla-
cebo. One hundred and seventy-seven patients, 18 to
65 years old, with cough due to uncomplicated upper re-
spiratory tract infections randomly received BHC
(24 mg/30 ml/day, n = 57), KJ syrup (30 ml/day, n = 66)
or placebo (n = 54) over a 5 day period. The primary
outcome was the reduction of cough frequency from
baseline assessed with a nominal 9 grade score. Both
BHC and KJ syrup were more effective than placebo for
cough relief. BHC showed a slightly longer latency of ef-
fect. Six patients in the BHC group reported minor ad-
verse events, which the authors did not treat.
Efficacy and tolerability of BHC in children
A substantial number of studies have investigated the
efficacy and tolerability of BHC in children. Most of the
studies were observational and empiric. Furthermore,
they were conducted when the drug was introduced to
the market. Almost all of these studies were based on
clinical evaluations and lacked objective methods for
the investigation of drug efficacy. Different formula-
tions of the drug were employed. No double blind stud-
ies were conducted with the drug alone and sample
sizes in these studies were small. Patients mainly pre-
sented with upper respiratory tract infections and stud-
ies were conducted with BHC alone or in association
with antibiotics (see Table 2).
Randomized controlled studies
A unique study conducted by Tarantino et al. investi-
gated the advantages of treatment with BHC (16 mg 3
times/day for 8 days) in 30 children (age range 3.5-12
years) with acute sinus inflammation in a placebo-
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controlled randomized study [44]. Amoxicillin was ad-
ministered orally to both groups of patients (50 mg/kg/
day) three times a day for the entire study period. Thera-
peutic efficacy was evaluated by monitoring signs and
symptoms of acute sinus inflammation (temperature,
pain, rhinitis, nasal secretions and hyperemia) and by X-
rays of the paranasal sinuses. Diagnostic X-ray images
were used as inclusion criteria and were controlled
30 days later. An arbitrary scale from 0 to 4 (0 = absent,
1 = slight, 2 = moderate, 3 = intense, 4 = very intense) was
used to evaluate pain, nasal secretions and rhinitis. Eval-
uations were performed on days 2, 4, 6 and 8 of treat-
ment. The results demonstrated a significant reduction
of nasal secretions (BHC group 0.06 vs placebo group
1.33) and an improvement of rhinitis (BHC group 0.42
versus 1.38 in the placebo group) (p < 0.01). The benefits
of treatment were evident on the second day of treat-
ment. Hyperemia of the nasal mucosa was significantly
reduced in the BHC group (p < 0.01). Pain persisted in 2
patients in the treatment group versus 5 patients in the
placebo group. The study also investigated days lost
from school; 11 days of school were lost in the treatment
group and 19 days of school were lost in the placebo
group. The authors concluded that the combination of
amoxicillin with BHC had a positive effect on acute
sinus inflammation. Treatment was well tolerated and
no side effects were attributed to the drug.
Observational studies
Observational studies have been performed on BHC since
its introduction to the market. Most of these were empiric
and were based on the clinical response to drug treatment.
Molina L. carried out an observational study that ex-
amined the therapeutic effect of Na-247 (the initial prep-
aration of BHC) in addition to the standard treatment in
48 infants (age range 1 month −4 years) affected by
pharyngo-bronchitis, bronchopneumonia, bronchopneu-
monia with tuberculosis and asthmatic bronchitis, with
primary symptoms of cough and difficult breathing [45].
Na-274 was administered (tablet or linctus) at a dose of
2–4 mg every 6 or 12 h. A control group of 20 children
of similar ages with similar diagnoses received specific
treatment without Na-247. The evaluation considered
the following parameters: time of disappearance of
symptoms upon auscultation, relief of breathing difficul-
ties and dyspnea disappearance and time to improve-
ment. The results were evaluated as very good
(improvement after 4 days of treatment observed in 24
cases) or good (improvement from day 5–8 observed in
18 cases). The study reported an improvement in less
than 4 days in 54.4% of the cases treated with Na-247
compared to 15% of the cases in the untreated group.
In another study, the efficacy of BHC administered at a
dose of 0.5 mg/kg/day (in three doses) in 30 children (up
to 14 years of age, of which 6 were <2 years old) with the
predominant clinical symptoms of mucus retention and
secretion in the respiratory tract was investigated by Fer-
nandes [46]. The main diagnoses in the children were
asthma (21 subjects), common cold (7 subjects) and bron-
chiolitis (2 subjects). Nineteen of the enrolled children also
received antibiotics and/or antipyretics, sedatives and nasal
decongestants. Treatment efficacy was evaluated by moni-
toring the children 4 consecutive times every 4 days. The
evolution of asthmatic crises, pulmonary auscultation and
cough were evaluated. The results were considered excel-
lent (no asthmatic crisis within 48 h, pulmonary ausculta-
tion revealed absence of rhonchi/wheezing or cough
disappeared within 8 days), good (asthma attacks reduced
by 50%, pulmonary auscultation close to normal or cough-
ing was no more wet). Excellent and good results were ob-
served in 71.4% and 28.6% of the asthmatic children,
respectively, and good results were observed in 42.8% of
the common cold patients. No improvement was reported
in children with bronchiolitis.
Brezina and Stachovà evaluated the therapeutic effects
of 7–10 days of treatment with an age related dose of
BHC by assessing clinical parameters in a group of 45
children (age range 1–8 years) with bronchitis [47]. Two
children also received antibiotics and 2 other children
received Alupent®. The authors reported that 4.4% of pa-
tients were lost during the study, 66.7% of the patients
were cured, 17.7% of patients showed improvement and
11.2% of patients showed no improvement. Cured was
defined as lung findings disappeared and children were
problem free.
A study by Okamoto et al. evaluated the clinical effect
of 1–2 weeks of treatment with BHC in 37 children of
various ages with cough, stridor and expectoration due
to various respiratory conditions [48], including bron-
chitis, the common cold, asthmatic bronchitis, asthma
and bronchiectasis. BHC was administered at various
doses ranging from 0.4-0.6 mg/kg. Previous drug treat-
ments were continued. The intensity and frequency of
cough, sputum quality, stridor, rhonchi, nasal discharge
and sleep disturbance were evaluated before and after
treatment. An overall assessment of the treatment was
classified as markedly effective: symptoms disappeared
or improved in 3–4 days of treatment (5.4% cases); ef-
fective: symptoms improved within 3–4 days and disap-
peared within 7 days (70.3%); moderately effective:
symptoms showed at least one grade of improvement
(16.2%); or ineffective: no improvement (8.1%). The spu-
tum stubbornness and the frequency of expectoration ef-
fectiveness were 85%, whereas the improvement of cough
was 90%. No side effects were reported in this study group.
Koga and Saito evaluated the efficacy of one week of
treatment with BHC at a dose of 0.02 g/kg/day in three
doses in 32 children (age range 3–9 years) with upper
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respiratory tract inflammation, acute bronchitis, bron-
chopneumonia and asthma [49]. A scoring system was
used to evaluate the improvement of difficulty in expec-
torating sputum, the character and amount of sputum,
cough, stridor, dyspnea, and rhonchus. General effective-
ness results showed a cumulative improvement in symp-
toms of 23.3-43.8%. The study reported a high degree of
improvement in the expectorability, character and
amount of sputum in 70-80% of the cases.
Comparative studies
In an open randomized comparative study, Camurri and
Marenco evaluated the efficacy and tolerability of 10 days
of treatment with BHC versus n-acetylcysteine in gran-
ule formulation in 32 children admitted to the hospital
with diagnoses of acute bronchitis [50]. Patients were
randomized to two matched treatment groups: the BHC
group (age range 2.3 ± 10.8) received BHC at a dose of
24 mg/day and the N-acetylcysteine (NAC) group (age
range 2.1 ± 11.11) received NAC at a dose of 300 mg/
day. Any antibiotic treatment that may have been started
before enrollment was continued throughout the study.
The efficacy of treatment was evaluated by monitoring
clinical parameters (fever, cough, breathlessness, quan-
tity and quality of expectoration, ease of expectoration
and auscultation of the chest) before and after treatment.
These parameters were evaluated with a semi quantita-
tive scale. The results demonstrated that the average
scores gradually declined in both study groups by the
end of treatment and non-significant differences were
observed for almost all signs. However, the onset of the
therapeutic action of BHC was faster, with a significant
reduction apparent on day 2. Ease of expectoration was
the only symptom that was significantly different be-
tween the two groups, in favor of the BHC group. Both
drugs were well tolerated and no significant adverse ef-
fects were reported.
In an open randomized study, Azzollini et al. evaluated
the efficacy and tolerability of two weeks of treatment
with Sobrerol (50–100 mg twice daily) versus BHC
(2–4 mg 3 times daily) in 40 children suffering from acute
hypersecretory bronchopulmonary diseases (acute, asth-
matic or recurrent bronchitis) [51]. A 3 day washout
period occurred before patients were randomized to either
the Sobrerol group (mean age of 43 + 18.8 months) or the
BHC group (mean age of 41 + 16.3 months). Clinical
symptoms were used to evaluate clinical efficacy. Body
temperature, general clinical conditions, dyspnea, cough
severity, sputum viscosity and volume, difficulty in expec-
toration and pathological sounds on thorax auscultation
were scored before and after treatment. Tolerability was
evaluated by reporting and describing any local or sys-
temic effects. A significant reduction of body temperature
(p < 0.05) was observed in both groups. In the Sobrerol
group, a significant improvement of dyspnea, cough sever-
ity, sputum viscosity and difficulty of expectoration scores
was observed (p < 0.05). In the BHC group, a statistically
significant improvement of general clinical conditions,
dyspnea and sputum viscosity was reported. The authors
reported no significant overall differences between the
two treatment groups. Both treatments demonstrated
similar improvement rates. Drugs were well tolerated in
both groups. The only reported slight side effects were:
cutaneous rash (1 patent in the Sobrerol group), diarrhea
(1 patient in the Sobrerol group and 1 patient in the
bromhexine group), nausea and regurgitation (2 patients
in the BHC group).
Boner et al. investigated the efficacy of combination
therapy with cephalexin and BHC in 100 children
(age range 2–13 years) with upper and lower tract in-
fections [52]. These patients were affected with acute
bronchitis, trachea-bronchitis, recurrent bronchitis, bron-
chopneumonia, purulent otitis and rhino-pharyngo-
tonsillitis with sinusitis. Cephalexin (80–100 mg/kg/day)
and BHC (0.6-0-8 mg/kg/day) were administered simul-
taneously three times a day for 5–12 days. Bacteriological
evaluation was carried out on sputum samples, pharyngeal
swabs, and aspirated tracheal or ear secretions depending
on disease presentation. A score system was used to evalu-
ate cough, temperature and sputum. Before treatment,
bacterial strains (probable etiological agents) were isolated
in 71 patients. The results demonstrated a complete recov-
ery in 66% of cases and a marked improvement in 27% of
cases. In 7% of cases, treatment failed. Clinical parameters
showed a favorable response in patients suffering from
acute infection compared to patients with recurrent infec-
tions. The only side effects registered were 3 cases of gas-
tric intolerance that did not require the discontinuation of
treatment. The authors concluded that treatment with
BHC and cephalexin was beneficial in pediatric patients
with respiratory tract infections.
Discussion
Mucociliary clearance, a vital mechanism of pulmonary
defense, requires the harmonization of many factors to
be effective, including efficient ciliary beating, a steady
mucus secretion rate, mucus rheology, and inherent
transportability. Mucoactive agents are widely indicated
in patients with acute and chronic broncho-pulmonary
disorders associated with abnormal mucus secretion and
impaired mucus transport [53]. The main purpose of
mucoactive drugs is to increase the ability to expectorate
sputum and/or decrease mucus hypersecretion. This in-
dication is very broad and may refer to several diseases
such as acute bronchitis, chronic bronchitis and chronic
obstructive pulmonary disease. While the physiopathol-
ogy of these diseases differs, the therapeutic effect of
mucoactive drugs was initially erroneously thought to be
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mediated by a similar mechanism of action. Updated
knowledge on the mucociliary complex system led to
the further classification of these drugs on the basis of
their action as expectorants, mucolytics, mucokinetic or
mucoregulatory agents. Clinical studies of these drugs
are still challenging, mainly due to a lack of objective pa-
rameters. The increased production and secretion of
mucus or the variability of mucus contents and conse-
quently the changes in the physico-chemical characteris-
tic of mucus are difficult to evaluate in vivo [54, 55]. For
example, one could think that expectorated sputum vol-
ume would be a good method for the assessment of the
effectiveness of a therapeutic agent, but expectorated
sputum volume relates poorly, at best, to improvements
in pulmonary function or to the clinical status of the pa-
tient [5]. This is partly due to the limitation of measur-
ing sputum volume because of patient reluctance to
expectorate instead of swallowing of the secretions. The
sputum volume also varies from day to day [5]. Further-
more, sputum contains various amounts of saliva and
secretions from the pharynx, larynx, nose and nasophar-
ynx as well as from the lungs.
BHC is a widely prescribed mucoactive over-the-
counter drug used to treat a range of respiratory condi-
tions, mainly conditions associated with mucus secretion
disturbances. These conditions are predominantly asso-
ciated with augmented inflammation and vulnerability to
the development of infections. After the registration of
BHC in Europe in 1963, numerous basic and clinical
studies were focused on investigating the efficacy of
BHC and understanding its mechanisms of action. In
the following 15 years, interest in the drug gradually de-
clined, although initial studies with BHC were of great
interest to the medical community. These initial studies
clearly suffer from a number of limitations and deficien-
cies. These studies were conducted in an era when
methodological approaches and good clinical practices
were not developed yet. In retrospect, these studies ap-
pear to lack a methodological approach and do not cor-
respond to the current requirements of evidence-based
medicine. Conflicting results were observed in the differ-
ent endpoints due to a lack of details provided in the de-
scription of the patients enrolled in the studies. Study
groups were heterogeneous and included patients with
various diseases with different pathophysiological char-
acteristics [54, 55]. Our understanding of respiratory dis-
eases has changed remarkably; we now recognize
different phenotypes and genotypes in a single disease
entity. Although assessment of clinical data confirm the
indication in all age groups, initial studies included pa-
tients with a wide range of ages and stratification by age
group was not considered essential.
In this review, we analyzed the major studies concern-
ing BHC. Several randomized controlled trials showed a
significant effect of BHC in patients with respiratory
conditions. Most of the patients in the studies were af-
fected by chronic obstructive bronchitis [33–40], and
mucus secretions seem to play a primary role in the
pathogenesis of the disease. A selection bias may be
present in studies from the pre computed tomography
era, leading to an underestimation of the prevalence of
specific conditions such as emphysema or bronchiec-
tasis. The low number of patients included in the studies
did not accurately reflect the number of individuals diag-
nosed with the condition [30, 34–36, 38, 40]. The mixed
clinical endpoints were not comparable because of a lack
of standardization of outcomes. Several studies used dif-
ferent generic nominal scales to assess symptoms and the
overall clinical evaluation was biased by the physicians’ at-
titudes and practice. Spirometric measures were signifi-
cantly different in a small number of placebo-controlled
trials [36, 38, 39]. The multicenter Italian study [39], one
of the largest studies evaluated, found a significant im-
provement in patients treated with BHC, although the pa-
tients exhibited a mean FEV1 of approximately 2 l.
BHC was shown to be safe in all studies. Studies in
children although substantial, have endpoints that de-
pend on the clinical evaluation of symptoms by physi-
cians or patients’ descriptions of symptoms such as
cough or expectoration. In most of the research reports,
only gastrointestinal intolerance and headache were re-
ported as side effects and were probably related to the
dose. However, the dosage and duration of treatment
varied. In light of the above findings, initial studies on
BHC were ignored by current researchers. A recent re-
view on clinical evidence for treatment of acute bron-
chitis referred to the placebo controlled study by
Nesswetha going back to 1967 [32] was mentioned in
the Cochrane review, showing a significant reduction of
the proportion of patients with frequent cough occur-
rence following bromhexine (12 mg/d) [55].
Indeed, Cochrane reviews on acute cough and bron-
chiectasis [55, 56] considered 4 studies on BHC/
ambroxol fulfilling the Cochrane RCT criteria, although
the studies have been done decades ago. The trials
assessed in the recent Cochrane review on OTC remed-
ies for acute cough in children and adults [55] showed
overall conflicting evidence for efficacy and thus did not
lead to a clear recommendation for or against the effect-
iveness of OTC cough medications evaluated. Further-
more, a large placebo effect is often detected in studies
that investigate respiratory conditions, particularly non-
serious, self-limiting conditions.
Recently, the Pharmacovigilance Risk Assessment
Committee (PRAC) of the European Medicines Agency
analyzed the balance of benefits and risks for Ambroxol
and BHC products and whether their approved indica-
tions are still positive [57].
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The clinical studies performed during the development
of bromhexine- and ambroxol-containing products be-
tween the 1950ies and 1980ies were considerably less
standardised than would be necessary today, and would
not completely fulfil contemporary requirements with
regard to validated endpoints, statistical confirmation, or
Good Clinical Practice (GCP). These constitute the major-
ity of the available evidence, in particular in the in-
dications that were first authorised (e.g. secretolytic
indication). This is not unexpected considering the meth-
odological challenges inherent to this therapeutic area and
evidential standards and requirements at the time when
these products were first developed. Often a large placebo
effect is seen in studies investigating respiratory condi-
tions, particularly in non-serious, self-limiting conditions.
Further, the definition of the relevant clinical endpoints
and the measurement of symptoms in these conditions
are challenging [54]. However, this is common for all
OTC products [55] showing conflicting evidence for effi-
cacy. Nevertheless, modest but positive results were re-
ported for ambroxol and bromhexine.
The Pharmacovigilance Risk Assessment Committee
(PRAC) following their recent risk-benefit evaluation of
all bromhexine/ambroxol products [57], as a conse-
quence, concluded that the benefit-risk balance of
ambroxol- and bromhexine-containing medicinal prod-
ucts remains favourable.
In studying the therapeutic efficacy of mucoactive
drugs, we still lack well-defined endpoints to be used in
clinical trials. The assessment of cough, expectoration
and dyspnea are difficult [58]. Furthermore, the decline
in lung function is associated with difficulty in expector-
ating secretions [5]. These parameters are difficult to
measure as clinical endpoints and are prone to variabil-
ity. In addition, we still lack long-term studies in this
field. Improving mucociliary clearance over time reduces
respiratory infections and halts the progression of ana-
tomical and functional damage in the respiratory tract.
Clinical evidence from these studies appears weak due
to a high degree of heterogeneity, few enrolled subjects,
difficulty in comparing endpoints and a lack of modern
scientific methodology. On the other hand, when consid-
ering data in support of BHC treatment, we found ro-
bust data from animal models that demonstrated that
BHC was a mucoactive drug. BHC is able to influence
mucus composition and in turn affects mucociliary ac-
tivity and cough with rare and mild side effects.
Conclusions
Although clinical evidence shows only modest but posi-
tive results, this does not mean that the drug’s efficacy is
disputable. BHC treatment is associated with favorable
improvements in mucus clearance and is indicated in
various respiratory disorders with abnormal mucus
secretion and impaired mucus transport. Furthermore,
BHC is well tolerated and studies showed low incidence
of mild side effects. Larger trials with adequate method-
ology are lacking in almost all OTC products and are in
general required to identify when the treatment can
improve the clinical outcome. Endpoints for future
studies should include quality of life questionnaires to
better assess the impact of treatment in the daily lives
of patients.
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